Ii

As ADCs continue to get incorporated in the treatment landscape across several solid tumors, data emerging from the next wave of ADCs add to the excitement.

Chinese pharmaceutical companies present both an opportunity and a threat to their international counterparts. In this blog, we explore what Western pharmaceutical businesses need to do as the world’s manufacturing hub begins building a reputation for quality.

The Chinese regulatory landscape is very different compared to that of the rest of the world. Can businesses bridge the gap between the East and West?

Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in AML.

Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in MM.

Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in CLL.

Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they might affect the treatment paradigm in DLBCL.

Last year, Prescient embarked upon the ambitious exercise of interviewing competitive intelligence (CI) practitioners across the pharmaceutical industry to provide insights regarding how intelligence was being prioritized by companies. With a focus on two open questions – “What challenges, threats and opportunities do you see?” and “What objectives, strategies and actions are imperative to ensure success?” – we were able to get a good picture of the developing landscape for CI.

How you spend your CI budget is as important as how much you are spending; therefore, it is vital to assess the upfront value associated with each potential project in order to ensure your money goes where it should and that the management team is happy.